756.38
price down icon0.94%   -7.14
pre-market  Vorhandelsmarkt:  762.78   6.40   +0.85%
loading
Schlusskurs vom Vortag:
$763.52
Offen:
$758.44
24-Stunden-Volumen:
253.56K
Relative Volume:
0.63
Marktkapitalisierung:
$46.29B
Einnahmen:
$3.06B
Nettoeinkommen (Verlust:
$1.28B
KGV:
35.52
EPS:
21.2963
Netto-Cashflow:
$447.35M
1W Leistung:
+0.75%
1M Leistung:
+18.64%
6M Leistung:
+27.89%
1J Leistung:
+41.18%
1-Tages-Spanne:
Value
$752.05
$767.97
1-Wochen-Bereich:
Value
$745.82
$779.03
52-Wochen-Spanne:
Value
$510.06
$779.03

Argen X Se Adr Stock (ARGX) Company Profile

Name
Firmenname
Argen X Se Adr
Name
Telefon
-
Name
Adresse
-
Name
Mitarbeiter
1,639
Name
Twitter
Name
Nächster Verdiensttermin
2024-10-31
Name
Neueste SEC-Einreichungen
Name
ARGX's Discussions on Twitter

Vergleichen Sie ARGX mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
ARGX
Argen X Se Adr
756.38 46.69B 3.06B 1.28B 447.35M 21.30
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
394.53 99.62B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
465.89 61.52B 2.46B -319.09M -52.09M -2.47
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
560.00 58.91B 14.21B 4.46B 3.56B 39.68
Biotechnology icon
ONC
Beone Medicines Ltd Adr
324.34 34.54B 3.81B -644.79M -669.77M -6.24

Argen X Se Adr Stock (ARGX) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-09-11 Herabstufung Deutsche Bank Buy → Hold
2025-08-25 Eingeleitet RBC Capital Mkts Outperform
2025-07-08 Hochstufung Deutsche Bank Hold → Buy
2025-07-03 Fortgesetzt Morgan Stanley Overweight
2025-05-13 Hochstufung Robert W. Baird Neutral → Outperform
2025-03-17 Hochstufung Bernstein Mkt Perform → Outperform
2025-03-12 Hochstufung Deutsche Bank Sell → Hold
2025-01-17 Herabstufung Deutsche Bank Hold → Sell
2024-11-12 Hochstufung Wolfe Research Peer Perform → Outperform
2024-11-05 Hochstufung Scotiabank Sector Perform → Sector Outperform
2024-11-01 Herabstufung Robert W. Baird Outperform → Neutral
2024-11-01 Hochstufung William Blair Mkt Perform → Outperform
2024-10-10 Fortgesetzt Raymond James Strong Buy
2024-10-04 Herabstufung Deutsche Bank Buy → Hold
2024-08-06 Hochstufung Barclays Equal Weight → Overweight
2024-07-25 Hochstufung Deutsche Bank Hold → Buy
2024-07-23 Hochstufung Oppenheimer Perform → Outperform
2024-02-15 Eingeleitet Wolfe Research Peer Perform
2023-12-20 Herabstufung Deutsche Bank Buy → Hold
2023-12-20 Herabstufung William Blair Outperform → Mkt Perform
2023-07-31 Eingeleitet Scotiabank Sector Perform
2023-07-24 Herabstufung UBS Buy → Neutral
2023-07-17 Fortgesetzt Evercore ISI Outperform
2023-06-15 Eingeleitet Societe Generale Sell
2023-05-31 Eingeleitet UBS Buy
2023-04-25 Eingeleitet Citigroup Buy
2023-03-14 Hochstufung Robert W. Baird Neutral → Outperform
2022-12-07 Eingeleitet William Blair Outperform
2022-10-12 Eingeleitet Oppenheimer Perform
2022-07-29 Herabstufung Robert W. Baird Outperform → Neutral
2022-06-28 Fortgesetzt Stifel Buy
2022-05-03 Hochstufung Morgan Stanley Equal-Weight → Overweight
2021-12-08 Eingeleitet Wells Fargo Overweight
2021-11-29 Hochstufung Piper Sandler Neutral → Overweight
2021-10-29 Hochstufung Guggenheim Neutral → Buy
2021-10-28 Hochstufung Raymond James Outperform → Strong Buy
2021-10-07 Eingeleitet Jefferies Buy
2021-09-23 Hochstufung Redburn Neutral → Buy
2021-09-07 Herabstufung Morgan Stanley Overweight → Equal-Weight
2021-07-23 Eingeleitet Deutsche Bank Hold
2021-07-19 Fortgesetzt Wolfe Research Outperform
2021-06-18 Eingeleitet UBS Buy
2021-06-04 Fortgesetzt Robert W. Baird Outperform
2021-05-10 Hochstufung H.C. Wainwright Neutral → Buy
2021-04-23 Eingeleitet Redburn Neutral
2021-03-05 Bestätigt H.C. Wainwright Neutral
2021-02-02 Herabstufung Piper Sandler Overweight → Neutral
2021-01-04 Herabstufung Guggenheim Buy → Neutral
2020-08-25 Eingeleitet Raymond James Outperform
2020-08-19 Herabstufung Evercore ISI Outperform → In-line
2020-07-29 Eingeleitet H.C. Wainwright Neutral
2020-02-10 Eingeleitet BofA/Merrill Buy
2019-11-05 Eingeleitet Credit Suisse Neutral
2019-10-31 Hochstufung William Blair Mkt Perform → Outperform
2019-10-22 Eingeleitet JP Morgan Overweight
2019-09-27 Eingeleitet Wells Fargo Market Perform
2019-09-16 Fortgesetzt Cowen Outperform
2019-06-28 Eingeleitet Robert W. Baird Outperform
2019-01-18 Fortgesetzt SunTrust Buy
2019-01-04 Eingeleitet Morgan Stanley Overweight
2018-12-17 Eingeleitet Goldman Buy
2018-12-14 Eingeleitet Wolfe Research Outperform
2018-06-29 Eingeleitet Nomura Buy
2018-04-09 Eingeleitet SunTrust Buy
2018-01-29 Bestätigt JMP Securities Mkt Outperform
Alle ansehen

Argen X Se Adr Aktie (ARGX) Neueste Nachrichten

pulisher
Sep 08, 2025

14 Newly Overvalued Stocks for the Week - Morningstar

Sep 08, 2025
pulisher
Sep 03, 2025

Argenx stock hits all-time high at 716.89 USD - Investing.com

Sep 03, 2025
pulisher
Aug 27, 2025

Stocks Showing Improving Market Leadership: argenx ADR Earns 84 RS Rating - MSN

Aug 27, 2025
pulisher
Aug 26, 2025

Argenx Stock Hits Record High After Reporting 664% Earnings Surge; This Rating Upgraded - Investor's Business Daily

Aug 26, 2025
pulisher
Aug 25, 2025

Argenx Tops Buy Point On Bullish Study, 850 Price Target - Investor's Business Daily

Aug 25, 2025
pulisher
Aug 25, 2025

Argenx: study met primary endpoint - AInvest

Aug 25, 2025
pulisher
Aug 25, 2025

argenx Announces Positive Topline Results from ADAPT SERON Study of VYVGART in Patients with AChR-Ab Seronegative gMG - GlobeNewswire Inc.

Aug 25, 2025
pulisher
Aug 21, 2025

Argenx Shares Rise 0.42% with $190M Volume Ranking 464th Amid Biotech Sector Surge - AInvest

Aug 21, 2025
pulisher
Aug 21, 2025

European ADRs Under Pressure: Sector Divergence and Strategic Entry Points - AInvest

Aug 21, 2025
pulisher
Aug 21, 2025

Earnings call transcript: Argenx Q2 2025 reports robust earnings beat - Investing.com

Aug 21, 2025
pulisher
Aug 19, 2025

Argenx's Growth Fuels Strong Demand for Vyvgart; Pipeline Continues to Develop - Morningstar

Aug 19, 2025
pulisher
Aug 17, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of argenx SE - GlobeNewswire Inc.

Aug 17, 2025
pulisher
Aug 15, 2025

This Stock Ran 31% In A Month. Will Upcoming News Revitalize It? - Investor's Business Daily

Aug 15, 2025
pulisher
Aug 08, 2025

argenx ADR Earns Relative Strength Rating Upgrade; Hits Key Benchmark - inkl

Aug 08, 2025
pulisher
Jul 31, 2025

Argenx NV ADR stock reaches all-time high at 689.13 USD By Investing.com - Investing.com South Africa

Jul 31, 2025
pulisher
Jul 31, 2025

Argenx NV ADR stock reaches all-time high at 689.13 USD - Investing.com Nigeria

Jul 31, 2025
pulisher
Jul 31, 2025

argenx ADR earnings beat by $3.26, revenue topped estimates - Investing.com South Africa

Jul 31, 2025
pulisher
Jul 21, 2025

Weekly Stock Grader Analysis: Upgrades & Downgrades on Top Blue-Chip Stocks - InvestorPlace

Jul 21, 2025
pulisher
Jul 03, 2025

Morgan Stanley assumes coverage on argenx stock with Overweight rating - Investing.com

Jul 03, 2025
pulisher
Jul 01, 2025

Argenx stock advances as H.C. Wainwright reiterates Buy rating - Investing.com

Jul 01, 2025
pulisher
Jun 30, 2025

Argenx stock falls after FDA flags serious risk signal with Vyvgart - Investing.com

Jun 30, 2025
pulisher
May 22, 2025

argenx SE’s SWOT analysis: biotech stock’s growth potential and challenges - Investing.com

May 22, 2025
pulisher
May 20, 2025

argenx ADR Shows Market Leadership With Jump To 84 RS Rating - Investor's Business Daily

May 20, 2025
pulisher
May 14, 2025

10 Stocks Analysts Are Upgrading Today - Insider Monkey

May 14, 2025
pulisher
May 09, 2025

Argenx Earnings: Vyvgart Delivers Strong Sales Growth; Prefilled Syringe Expands Patient Access - Morningstar

May 09, 2025
pulisher
May 09, 2025

Metric Analysis: Argen X SE ADR (ARGX)’s Key Ratios in the Limelight - DWinneX

May 09, 2025
pulisher
May 09, 2025

Analyzing Ratios: Symbotic Inc (SYM)’s Financial Story Unveiled - DWinneX

May 09, 2025
pulisher
May 08, 2025

Biotech Tumbles. Why Its Sales Beat Wasn't Enough. - Investor's Business Daily

May 08, 2025
pulisher
May 08, 2025

argenx ADR earnings beat by $0.34, revenue topped estimates - Investing.com Nigeria

May 08, 2025
pulisher
May 08, 2025

Crude Oil Gains Over 2%; US Foods Posts Downbeat Earnings - Benzinga

May 08, 2025
pulisher
Apr 30, 2025

Argenx Stock Extends Rally In A Base As Earnings Loom - Investor's Business Daily

Apr 30, 2025
pulisher
Apr 14, 2025

argenx ADR Earns Relative Strength Rating Upgrade - inkl

Apr 14, 2025
pulisher
Apr 12, 2025

Argenx stock target holds at $720, H.C. Wainwright affirms Buy rating By Investing.com - Investing.com South Africa

Apr 12, 2025
pulisher
Apr 11, 2025

Biotech Leader Surges On 'Best-Case Scenario' For Key Drug - Investor's Business Daily

Apr 11, 2025
pulisher
Apr 11, 2025

Guggenheim maintains Buy on Argenx stock, target at $1,100 - Investing.com India

Apr 11, 2025
pulisher
Apr 11, 2025

Guggenheim maintains Buy on Argenx stock, target at $1,100 By Investing.com - Investing.com South Africa

Apr 11, 2025
pulisher
Apr 11, 2025

Argenx stock target holds at $720, H.C. Wainwright affirms Buy rating - Investing.com India

Apr 11, 2025
pulisher
Apr 11, 2025

Stifel maintains $780 target on argenx stock after FDA nod - Investing.com

Apr 11, 2025
pulisher
Apr 04, 2025

Stocks To Watch: argenx ADR Sees RS Rating Jump To 91 - Investor's Business Daily

Apr 04, 2025
pulisher
Mar 17, 2025

Bernstein double upgrades Argenx to "outperform," raises price target to €755 By Investing.com - Investing.com South Africa

Mar 17, 2025
pulisher
Mar 17, 2025

Bernstein double upgrades Argenx to "outperform," raises price target to €755 - Investing.com

Mar 17, 2025
pulisher
Mar 17, 2025

Bernstein raises argenx stock rating, hikes target to EUR755 - Investing.com

Mar 17, 2025

Finanzdaten der Argen X Se Adr-Aktie (ARGX)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
biotechnology ONC
$324.34
price down icon 3.38%
$560.00
price down icon 1.44%
$465.89
price down icon 0.57%
$145.93
price up icon 0.10%
$96.74
price down icon 7.26%
Kapitalisierung:     |  Volumen (24h):